ReviewSeminars in nuclear medicine2016
PSMA PET and Radionuclide Therapy in Prostate Cancer.
Review in Seminars in nuclear medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Meta-analysis ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023Pooled it
- PSMA-Targeted Liposomes for Therapeutic Delivery into a Prostate Cancer Cell Model.Pharmaceutics · 2026Article
- PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.The Prostate · 2026Article
- Article
- Role of PSMA PET/CT in imaging and management of prostate cancer.Current opinion in oncology · 2025Review
- Evaluating the Potential of PSMA Targeting in CNS Tumors: Insights from Large-Scale Transcriptome Profiling.Cancers · 2025Article
- JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Novel astatine (European journal of nuclear medicine and molecular imaging · 2025Article
- PSMA imaging as a non-invasive tool to monitor inducible gene expression in vivo.EJNMMI research · 2024Article
- Development and Characterization ofInternational journal of molecular sciences · 2023Article
- Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection.International urology and nephrology · 2023Article
- Diagnostic value of two-time point [Scientific reports · 2023Article
- Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.Signal transduction and targeted therapy · 2022Review
- Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center.European journal of nuclear medicine and molecular imaging · 2022Article
- Advances in PSMA-targeted therapy for prostate cancer.Prostate cancer and prostatic diseases · 2022Review
- Current Opinion on the Use of Magnetic Resonance Imaging in Staging Prostate Cancer: A Narrative Review.Cancer management and research · 2022Review
- Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [Molecular imaging and biology · 2021Article
- Near infrared photoimmunotherapy of cancer; possible clinical applications.Nanophotonics (Berlin, Germany) · 2021Review
- How Different Albumin-Binders Drive Probe Distribution of Fluorescent RGD Mimetics.Frontiers in chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Prostate cancer (PCa) is the most common malignancy in men and a major cause of cancer death. Accurate imaging plays an important role in diagnosis, staging, restaging, detection of biochemical recurrence, and for therapy of patients with PCa. Because no effective treatment is available for advanced PCa, there is an urgent need to develop new and more effective therapeutic strategies. To optimize treatment outcome, especially in high-risk patients with PCa, therapy for PCa is moving rapidly toward personalization. Medical imaging, including positron emission tomography (PET)/computed tomography (CT), plays an important role in personalized medicine in oncology. In the recent years, much focus has been on prostate-specific membrane antigen (PSMA) as a promising target for imaging and therapy with radionuclides, as it is upregulated in most PCa. In the prostate, one potential role for PSMA PET imaging is to help guide focal therapy. Several studies have shown great potential of PSMA PET/CT for initial staging, lymph node staging, and detection of recurrence of PCa, even at very low prostate-specific antigen values after primary therapy. Furthermore, studies have shown that PSMA PET/CT has a higher detection rate than choline PET/CT. Radiolabeled PSMA ligands for therapy show promise in several studies with metastatic PCa and is an area of active investigation. The "image and treat" strategy, with radiolabeled PSMA ligands, has the potential to improve the treatment outcome of patients with PCa and is paving the way for precision medicine in PCa. The aim of this review is to give an overview of recent advancement in PSMA PET and radionuclide therapy for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.